Oral Ozempic Reformulation Released for Type 2 Diabetes
A reformulated oral Ozempic tablet is now available for type 2 diabetes, offering a new daily pill option with lower doses.
08 May 2026
Oral GLP-1s Impact Brain Reward Circuitry
Oral small-molecule GLP-1 drugs suppress hedonic feeding in mice by modulating brain reward circuits, with implications for other reward-related dysfunctions.
06 May 2026
GLP-1 Reduces Heavy Drinking in Clinical Trial
Weekly semaglutide with CBT significantly reduced heavy drinking in alcohol use disorder & obesity patients, per a clinical trial.
04 May 2026
Weight Loss Reverses Cardiac Dysfunction in Severe Obesity
Weight loss can restore heart muscle function in severe obesity by reversing protein changes linked to heart failure.
02 May 2026
GLP-1 Hormone Found in Joint Fluid, Potential for Arthritis Treatment
Natural GLP-1 hormone has been detected in joint fluid, indicating a potential direct therapeutic pathway for GLP-1-based drugs in arthritis treatment.
02 May 2026
GLP-1 Medications Primarily Reduce Fat, Not Muscle Mass
GLP-1 meds cause significant fat loss with minimal muscle loss over 12 months, proving their weight management efficacy.
02 May 2026
GLP-1 Study Finds Differences in Lean Mass Loss
GLP-1 study reports semaglutide preserved lean mass better than tirzepatide, with a 2% higher lean mass loss on tirzepatide over 12 months.
28 Apr 2026
